Back to today’s briefing

Story perspectives

Eli Lilly's Orforglipron Shines in Diabetes Trials, Eyes $470B Market

4/21/2025

50 9

Summary

Story summary

Eli Lilly's Orforglipron, a groundbreaking oral medication for type 2 diabetes and weight loss, has excelled in Phase 3 trials, matching the effectiveness of injectable treatments. As Lilly gears up for U.S. manufacturing expansion, it seeks to bolster drug supply security in a booming GLP-1 market, expected to reach a staggering $470 billion by 2030.

1 of 1

Story summary

Eli Lilly's Orforglipron, a groundbreaking oral medication for type 2 diabetes and weight loss, has excelled in Phase 3 trials, matching the effectiveness of injectable treatments. As Lilly gears up for U.S. manufacturing expansion, it seeks to bolster drug supply security in a booming GLP-1 market, expected to reach a staggering $470 billion by 2030.